Tapan Kadia

Tapan Kadia, MD
- Leukemia Doc at MD Anderson Cancer Center
Leukemia, clinical/translational research. Views, posts and opinions shared are my own.

[Naveen Pemmaraju, MD @doctorpemm]

👏Important new paper from our group led by .@TapKadia & @AlexBataller 👉just out in @AjHematology | #Cladribine #leusm #endcancer | @sanamloghavi

https://t.co/9DvxtV8czK

[UT MD Anderson @UTMDAnderson]

Results from a Phase 2 trial showed that a lower-intensity treatment regimen may be highly effective in some subsets of patients with acute myeloid leukemia.

Learn more: https://t.co/IYwvmqaB7N @tapkadia #EndCancer

[Tapan Kadia @TapKadia]

Our most recent update of CLAD+LDAC+Ven now published - almost 200 pts with ~3yr f/u ; CR rate 84% and 92% in TP53 wildtype. @alexbataller https://t.co/t7VBN447v9

[Hagop Kantarjian,MD @DrHKantarjian]

Triple- nucleosides plus venetoclax result in outstanding outcomes in older #AML

https://t.co/sIawuDmsAR

@AjHematology @UTMDAnderson

[William D. Marrero @wdmarrero]

Just wrapped up an incredible ASH convention! Grateful for the opportunity to be part of the leukemia fellowship @MDAndersonNews @garciamanero @TapKadia @r_sazevedo #leukemia #ASH25 @Apsingh_MD

[Tapan Kadia @TapKadia]

Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews

[PeerView @PeerView]

Big thanks to Drs. David A. Sallman, @Tapkadia and @dremmasearle for an outstanding #ASH25 #AML session—packed with practical insights for everyday clinical care.

📺 Catch the replay: https://t.co/iUApohITS3

Grateful for grant support from @JNJInnovMed, @kuraoncology and @Syndax, and for our collaboration with @HealthTree! #CME #MedEd

[Naveen Pemmaraju, MD @doctorpemm]

#ASH25 | Wow!! Thanks 🙏 to @ASH_hematology for featuring our @MDAndersonNews Leukemia team in the #ASH25 Program Guide with the reminder save the date for #ASH26 !!!!! | @TapKadia @drsangeetmd @JenMarvinPeek @HannahGoulart @doctorpemm @CRausch_PharmD @FadiHaddad_MD @NitinJainMD

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Our latest from @MDAndersonNews sharing the largest series of these cases to date.
https://t.co/mYxYYqJeGe
@jenweiying @TapKadia @BrJHaem

[Nicolas Duployez @NicolasDuployez]

Read the cell, guess the genetics.
#HemePath #Genetics #leusm #AMLsm 🔬🧬🩸

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML. 
 🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️
 🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.
 🔴 NPM1 wildtype relapses occur later and often had MR mutations.  And ALL (8/8) had a different flow immunophenotype compared to original AML.
 🔴We proposed that these were ‘new’ AMLs, that arose from common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’.

https://t.co/MTYuZEW15S
@AjHematology

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory #AML @TapKadia @AjHematology

https://t.co/rZu43anEVS

[Society of Hematologic Oncology (SOHO) @SocietyofHemOnc]

Triplet therapy maintains, improves quality of life in relapsed/refractory myeloma
https://t.co/aog6EUOLOF

[Naval Daver, M.D. @Daver_Leukemia]

Very much looking forward to this meeting. Looking forward to great discussions and presentations from key US and international leaders on AML & ALL. Hoping you can join! @_MDEducation @jaltmanmd @TapKadia @doctorpemm @Ramikomrokji

[Fadi Haddad, MD @FadiHaddad_MD]

👉 Check the Top #ALL #abstracts at #EHA2025 by date and ID

Many presented by our #Leukemia Faculty from @MDAndersonNews

Looking forward to exciting discussions & new treatment options for patients at @EHA_Hematology @OncoAlert @ALL_Hub_ #leusm

[Fadi Haddad, MD @FadiHaddad_MD]

👉 Check the Top #AML #abstracts at #EHA2025 by date and ID

Many presented by our #Leukemia Faculty & Fellows from @MDAndersonNews

Looking forward to exciting discussions & new treatment options for patients at @EHA_Hematology @OncoAlert @AML_Hub #leusm

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful to get to spend some time with our friend & colleague @CRausch who is back in town this weekend ! @Marxk @TapKadia | #leusm

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis | Led by .@Daver_Leukemia & @HusseinAbbasLab https://t.co/xbrGUO01VW | @MDAndersonNews #leusm #endcancer @CCR_AACR @CD_AACR

[Tapan Kadia @TapKadia]

@doctorpemm @Aiims1742 @nyulangone @Perlmutter_CC @NitinJainMD @Daver_Leukemia @GBorthakur Congrats @Aiims1742 !

[Tapan Kadia @TapKadia]

@Aiims1742 @nyulangone @Perlmutter_CC Congratulations @Aiims1742 ! We’ll miss you at MDACC